Capricor Therapeutics Target of Unusually High Options Trading (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) was the recipient of some unusual options trading on Thursday. Stock investors bought 11,316 call options on the stock. This represents an increase of approximately 214% compared to the average daily volume of 3,599 call options.

Analyst Ratings Changes

CAPR has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a report on Monday. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Hedge Funds Weigh In On Capricor Therapeutics

Several large investors have recently bought and sold shares of CAPR. Vanguard Group Inc. lifted its position in Capricor Therapeutics by 44.4% in the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock valued at $31,420,000 after acquiring an additional 700,243 shares during the last quarter. Farallon Capital Management LLC purchased a new position in Capricor Therapeutics during the 4th quarter worth approximately $31,056,000. Geode Capital Management LLC lifted its stake in Capricor Therapeutics by 37.8% in the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock valued at $12,139,000 after buying an additional 241,279 shares during the last quarter. Altium Capital Management LLC boosted its holdings in shares of Capricor Therapeutics by 150.5% in the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock valued at $9,853,000 after acquiring an additional 429,000 shares during the period. Finally, Woodline Partners LP acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at $8,693,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR traded up $2.47 during trading on Thursday, reaching $14.69. The stock had a trading volume of 2,210,259 shares, compared to its average volume of 1,369,690. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The company has a market cap of $667.95 million, a P/E ratio of -13.88 and a beta of 4.10. The business’s 50-day moving average price is $14.05 and its 200-day moving average price is $14.50.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The company had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $9.87 million. Analysts forecast that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.